Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Vincamine is a peripheral vasodilator, that increases blood flow to the brain. Vincamine is a potent neuroprotector and cerebral vasodilator that is poorly soluble and used to treat disorders of the central nervous system. Sometimes the co-administration of other components has a significant impact on the bioavailability of pure compounds, and other times the so-called "phytocomplex" may improve the absorption of particular phytochemicals.
ln Vitro |
Vincamine (20, 40, and 80 μM; 24 hours) protects human corneal epithelial cells (HCECs) from lipopolysaccharide (LPS) in a significant, concentration-dependent manner[1].
Vincamine (20, 40 and 80 μM; 24 hours) dramatically lowers the level of reactive oxygen species (ROS) in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Furthermore, following Vincamine administration, MDA levels are also markedly lowered while T-AOC and SOD levels rise in a dose-dependent manner[1]. Vincamine (20, 40 and 80 μM; 24 hours) dose-dependently restores TrxR activity in HCECs. Nevertheless, neither LPS nor Vincaminer can activate nor inhibit the intracellular activities of Trx, GR, or GPx[1]. Vincamine could activate GPR40 (EC50=6.28 µM) while DHA (a GPR40 ligand) served as a positive control (EC50=3.85 µM) in hGPR40-CHO cells[2]. |
---|---|
ln Vivo |
Vincamine (intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It successfully reduces glycated hemoglobin and fasting blood glucose levels. In addition, it improves glucose-induced plasma insulin concentration and oral glucose tolerance without affecting basal insulin secretion in vivo[2].
|
Animal Protocol |
Male and female db/db mice (BKS.Cg-Dock7m+/+Leprdb/J) and HFD/STZ-induced type 2 diabetic model mice
15 and 30 mg/kg/day Intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks |
References |
|
Molecular Formula |
C21H26N2O3
|
---|---|
Molecular Weight |
354.4427
|
Exact Mass |
354.19
|
Elemental Analysis |
C, 71.16; H, 7.39; N, 7.90; O, 13.54
|
CAS # |
1617-90-9
|
Related CAS # |
42971-09-5 (Vinpocetine); 4880-92-6 (Apovincamine); 4429-63-4 (Tabersonine); 4880-88-0 (CH846; CH-846; CH 846; Vinburnine; Eburnal; Eburnamonine); 19877-89-5 (Vincanol; Vincanolum); 68779-67-9 (Vindeburnol)
|
Appearance |
Solid powder
|
SMILES |
CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O
|
InChi Key |
RXPRRQLKFXBCSJ-GIVPXCGWSA-N
|
InChi Code |
InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
|
Chemical Name |
methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
|
Synonyms |
Vincamine; Vinca Minor extract; periwinkle extract; Angiopac; Devincan; Equipur; Minorin; Novicet; Oxybral; Perval; Sostenil; Tripervan
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 3~25 mg/mL (8.5~70.5 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8214 mL | 14.1068 mL | 28.2135 mL | |
5 mM | 0.5643 mL | 2.8214 mL | 5.6427 mL | |
10 mM | 0.2821 mL | 1.4107 mL | 2.8214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Chemical structure of vincamine. Am J Transl Res . 2018 Jul 15;10(7):2195-2204. eCollection 2018. td> |
Vincamine increased the viability of LPS treated HCECs. Am J Transl Res . 2018 Jul 15;10(7):2195-2204. eCollection 2018. td> |
Effects of vincamine on the production of ROS, SOD, MDA, and T-AOC in LPS treated HCECs. Am J Transl Res . 2018 Jul 15;10(7):2195-2204. eCollection 2018. td> |